Toxic tau: structural origins of tau aggregation in Alzheimer's disease
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- review article
- Published by Medknow in Neural Regeneration Research
- Vol. 15 (8), 1417-1420
- https://doi.org/10.4103/1673-5374.274329
Abstract
Alzheimer’s disease is characterized by the extracellular accumulation of the amyloid β in the form of amyloid plaques and the intracellular deposition of the microtubule-associated protein tau in the form of neurofibrillary tangles. Most of the Alzheimer’s drugs targeting amyloid β have been failed in clinical trials. Particularly, tau pathology connects greatly in the pathogenesis of Alzheimer’s disease. Tau protein enhances the stabilization of microtubules that leads to the appropriate function of the neuron. Changes in the quantity or the conformation of tau protein could affect its function as a microtubules stabilizer and some of the processes wherein it is involved. The molecular mechanisms leading to the accumulation of tau are principally signified by numerous posttranslational modifications that change its conformation and structural state. Therefore, aberrant phosphorylation, as well as truncation of tau protein, has come into focus as significant mechanisms that make tau protein in a pathological entity. Furthermore, the shape-shifting nature of tau advocates to comprehend the progression of Alzheimer’s disease precisely. In this review, we emphasize the recent studies about the toxic and shape-shifting nature of tau in the pathogenesis of Alzheimer’s disease.Keywords
This publication has 39 references indexed in Scilit:
- The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patientsActa Neuropathologica Communications, 2014
- Soluble -Synuclein Is a Novel Modulator of Alzheimer's Disease PathophysiologyJournal of Neuroscience, 2012
- Tau as a therapeutic target in neurodegenerative diseasePharmacology & Therapeutics, 2012
- The Amyloid State of Proteins in Human DiseasesCell, 2012
- Trans-Synaptic Spread of Tau Pathology In VivoPLOS ONE, 2012
- Propagation of Tau Pathology in a Model of Early Alzheimer's DiseaseNeuron, 2012
- Understanding the Kinetic Roles of the Inducer Heparin and of Rod-like Protofibrils during Amyloid Fibril Formation by Tau ProteinJournal of Biological Chemistry, 2011
- Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependentNature Structural & Molecular Biology, 2011
- Quantitative Characterization of Heparin Binding to Tau ProteinJournal of Biological Chemistry, 2010
- Assembly of two distinct dimers and higher‐order oligomers from full‐length tauEuropean Journal of Neuroscience, 2007